Norbert Hilf
Immatics Biotechnologies (Germany)(DE)
Publications by Year
Research Areas
CAR-T cell therapy research, Cancer Research and Treatments, Immunotherapy and Immune Responses, Biomedical Ethics and Regulation, Cancer Immunotherapy and Biomarkers
Most-Cited Works
- → Actively personalized vaccination trial for newly diagnosed glioblastoma(2018)908 cited
- → Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival(2012)779 cited
- → The Endoplasmic Reticulum-resident Heat Shock Protein Gp96 Activates Dendritic Cells via the Toll-like Receptor 2/4 Pathway(2002)484 cited
- → The heat shock protein gp96 induces maturation of dendritic cells and down-regulation of its receptor(2000)370 cited
- → Cross-Presentation of Glycoprotein 96–Associated Antigens on Major Histocompatibility Complex Class I Molecules Requires Receptor-Mediated Endocytosis(1999)349 cited
- → Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses(2008)283 cited
- → Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy(2012)200 cited
- → A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multipeptide Therapeutic Vaccine) in Patients with Newly Diagnosed Glioblastoma(2016)161 cited
- → The heat shock protein gp96: a receptor-targeted cross-priming carrier and activator of dendritic cells(2000)84 cited
- → Human platelets express heat shock protein receptors and regulate dendritic cell maturation(2002)82 cited